Time-dependent pharmacodynamics of amikacin on Mycobacterium abscessus growth and resistance emergence

ABSTRACTMycobacterium abscessus pulmonary disease is increasing in prevalence globally, particularly for individuals with cystic fibrosis. These infections are challenging to treat due to a high rate of resistance. Amikacin is critical to treatment, but the development of toxicity, amikacin resistan...

Full description

Bibliographic Details
Published in:	Microbiology Spectrum
Main Authors:	Joy E. Gibson, Nishant Nandanwar, Michael N. Neely
Format:	Article
Language:	English
Published:	American Society for Microbiology 2024-02-01
Subjects:	amikacin aminoglycosides Mycobacterium abscessus NTM pharmacokinetics pharmacodynamics
Online Access:	https://journals.asm.org/doi/10.1128/spectrum.03222-23

Similar Items

Rapid Detection of Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex by High-Resolution Melting Curve Analysis
by: Haoran Li, et al.
Published: (2022-06-01)

Treatment Outcome in Patients with <i>Mycobacterium abscessus</i> Complex Lung Disease: The Impact of Tigecycline and Amikacin
by: Jeng-How Yang, et al.
Published: (2022-04-01)

The Use of Amikacin Liposome Inhalation Suspension (Arikayce) in the Treatment of Refractory Nontuberculous Mycobacterial Lung Disease in Adults
by: Khan O, et al.
Published: (2020-06-01)

Poor efficacy of the combination of clarithromycin, amikacin, and cefoxitin against Mycobacterium abscessus in the hollow fiber infection model
by: Etienne Vignaud, et al.
Published: (2025-01-01)

Antibiotic Sensitivity Testing and Molecular Characteristics Related to Clarithromycin and Amikacin Resistance in Mycobacterium abscessus Complex Isolated from Patients with Pulmonary Infection at National Hospital 74, Vietnam
by: Vu Thi Thuong, et al.
Published: (2025-07-01)

The effects of silver nitrate on Mycobacterium abscessus biofilms in a simulated antimicrobial showerhead environment
by: Sarah Pitell, et al.
Published: (2025-05-01)

Challenges in achieving the guideline-recommended amikacin level for Mycobacterium avium complex pulmonary disease
by: Takuya Akutsu, et al.
Published: (2025-05-01)

Polymicrobial interactions influence Mycobacterium abscessus co-existence and biofilm forming capabilities
by: Nishant Nandanwar, et al.
Published: (2024-11-01)

Molecular Identification of Strains within the Mycobacterium abscessus Complex and Determination of Resistance to Macrolides and Aminoglycosides
by: Kania Katarzyna, et al.
Published: (2023-12-01)

Efficacies of omadacycline + amikacin + imipenem and an all-oral regimen omadacycline + clofazimine + linezolid in a mouse model of M. abscessus lung disease
by: Elisa H. Ignatius, et al.
Published: (2024-07-01)

Analysis of Phenotypic and Genotypic Susceptibility to Clarithromycin and Amikacin of <i>Mycobacterium abscessus</i> Complex Strains Isolated from Cystic Fibrosis Patients
by: Juan Carlos Cao Yao, et al.
Published: (2023-11-01)

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings
by: Morita A, et al.
Published: (2022-07-01)

Amikacin use in critically ill patients requiring renal replacement therapy: the AMIDIAL-ICU study
by: Vincent Dupont, et al.
Published: (2025-03-01)

Pathogen genotypes and host phenotypes of Mycobacterium abscessus pulmonary disease in Taiwan
by: Yu-Hsun Chiang, et al.
Published: (2025-10-01)

Mycobacterium abscessus Complex Infections in Humans
by: Meng-Rui Lee, et al.
Published: (2015-09-01)

Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease
by: A. Lemson, et al.
Published: (2024-06-01)

Microbiological persistence in patients with Mycobacterium abscessus complex lung disease: The prevalence, predictors, and the impact on progression
by: Ling-Kai Chang, et al.
Published: (2024-02-01)

Luciferase reporter mycobacteriophage (TM4::GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex
by: Saranathan Rajagopalan, et al.
Published: (2025-09-01)

Optimal Amikacin Levels for Patients with Sepsis in Intensive Care Unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia
by: Gestina Aliska, et al.
Published: (2017-11-01)

Optimal Amikacin Levels for Patients with Sepsis in Intensive Care Unit of Cipto Mangunkusumo Hospital, Jakarta, Indonesia
by: Gestina Aliska, et al.
Published: (2017-11-01)

Alternatives to Antibiotics against <i>Mycobacterium abscessus</i>
by: Antonio Broncano-Lavado, et al.
Published: (2022-09-01)

Amikacin: Area Under Curve for Once Daily Dose and Its Correlation with Plasma Concentration at Six Hours Post Infusion
by: Teera Kolladaruengkri, et al.
Published: (2003-03-01)

Population Pharmacokinetics of Amikacin in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation
by: Claire Pressiat, et al.
Published: (2022-01-01)

Outcomes of pulmonary Mycobacterium abscessus infection
by: William G Flight, et al.
Published: (2020-01-01)

Initial In Vivo Evaluation of a Novel Amikacin-Deoxycholate Hydrophobic Salt Delivers New Insights on Amikacin Partition in Blood and Tissues
by: Styliani Xiroudaki, et al.
Published: (2021-01-01)

Unfolding Mycobacterium abscessus outbreak: a case study of mesotherapy-associated Mycobacterium abscessus infection
by: Phoebe Kar Wai Lam, et al.
Published: (2024-06-01)

Efficacy of Omadacycline-Containing Regimen in a Mouse Model of Pulmonary Mycobacteroides abscessus Disease
by: Binayak Rimal, et al.
Published: (2023-04-01)

Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin
by: Jonás Samuel Pérez-Blanco, et al.
Published: (2021-02-01)

Demographic and clinical features of nontuberculous mycobacteria infection resulting from cosmetic procedures: a systematic review
by: Xiao Ma, et al.
Published: (2024-12-01)

Amikacin Liposomal Inhalation Suspension for Non-Tuberculous <i>Mycobacteria</i> Lung Infection: A Greek Observational Study
by: Angeliki A. Loukeri, et al.
Published: (2024-10-01)

Evaluation of Intra-Articular Amikacin Administration in an Equine Non-inflammatory Joint Model to Identify Effective Bactericidal Concentrations While Minimizing Cytotoxicity
by: Lynn Pezzanite, et al.
Published: (2021-05-01)

Mycobacterium abscessus complex: A Review of Recent Developments in an Emerging Pathogen
by: Laura Victoria, et al.
Published: (2021-04-01)

In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus
by: Yu Q, et al.
Published: (2025-10-01)

Omadacycline for the treatment of Mycobacterium abscessus infections: Case series and review of the literature
by: Ayesha Siddiqa, et al.
Published: (2023-01-01)

Screening of TB Actives for Activity against Nontuberculous Mycobacteria Delivers High Hit Rates
by: Jian Liang Low, et al.
Published: (2017-08-01)

Glomerular Filtration Rate Changes in Neonates with Sepsis Treated with Amikacin and Cefotaxime
by: Fatemeh-Sadat Tabatabaei, et al.
Published: (2022-01-01)

Mycobacterium Abscessus – Diagnostic and Therapeutic Frontiers in Infection Management
by: Masiarova Simona, et al.
Published: (2023-12-01)

Evaluation of the cross-immunity between Mycobacterium tuberculosis and Mycobacterium abscessus in vitro
by: Da Xu, et al.
Published: (2025-01-01)

Discovery of Biofilm-Inhibiting Compounds to Enhance Antibiotic Effectiveness Against <i>M. abscessus</i> Infections
by: Elizaveta Dzalamidze, et al.
Published: (2025-02-01)

Efficacy of carbonyl cyanide-3-chlorophenylhydrazone in combination with antibiotics against Mycobacterium abscessus
by: Jifang Zheng, et al.
Published: (2025-02-01)